title: Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
abstract: OBJECTIVE
  The natural history and optimal management of serous tubal intraepithelial carcinoma (STIC), regardless of BRCA status, is unknown. We report the follow-up findings of a series of incidental fallopian tube high-grade serous carcinomas (HGSCs) and STICs identified in women at low risk for hereditary breast and ovarian cancer (HBOC), undergoing surgery for other indications.
  
  
  METHODS
  Cases of incidental STIC and HGSC were identified from 2008. Patients with known BRCA1 or BRCA2 mutations, or a family history of ovarian or breast cancer before the diagnosis of STIC or HGSC were excluded. A retrospective chart review was conducted to obtain clinical data.
  
  
  RESULTS
  Eighteen cases were identified with a median follow-up of 25 months (range, 4-88 months). Twelve of 18 patients had a diagnosis of STIC with no associated invasive HGSC and 6 had STIC associated with other invasive malignancies. Completion staging surgery was performed on 7 of the 18 patients, including 5 of 12 in which there was STIC only identified on primary surgery; 3 cases were upstaged from STIC only to HGSC based on the staging surgery. Recurrence of HGSC occurred in 2 of the 18 patients. BRCA testing was performed on 3 patients, 1 of whom tested positive for a pathogenic BRCA1 mutation.
  
  
  CONCLUSIONS
  Our study suggests that completion staging surgery for incidental STICs in non-BRCA patients may be considered. These patients should be offered hereditary testing. The Pelvic-Ovarian cancer INTerception (POINT) Project is an international registry set up to add to our understanding of STICs.
authors.affiliation: *Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; †National Cancer Centre Singapore, Singapore; ‡Department of Pathology, Belfast Health and Social Care Trust, Belfast, United Kingdom; §Department of Laboratory Medicine and Pathology, Royal Alexandra Hospital, University of Alberta, Edmonton; ∥Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta; ¶Department of Pathology, Royal Jubilee Hospital and the University of British Columbia, Victoria, British Columbia, Canada; #Department of Oncology, NI Cancer Centre, Belfast Health and Social Care Trust, Belfast, United Kingdom; and **Department of Pathology, Vancouver General Hospital and the University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Wen Yee
authors.initials: WY
authors.lastname: Chay
authors.forename: W Glenn
authors.initials: WG
authors.lastname: McCluggage
authors.forename: Cheng-Han
authors.initials: CH
authors.lastname: Lee
authors.forename: Martin
authors.initials: M
authors.lastname: Köbel
authors.forename: Julie
authors.initials: J
authors.lastname: Irving
authors.forename: Joanne
authors.initials: J
authors.lastname: Millar
authors.forename: C Blake
authors.initials: CB
authors.lastname: Gilks
authors.forename: Anna V
authors.initials: AV
authors.lastname: Tinker
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D002170:Canada; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D005185:Fallopian Tube Neoplasms / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human